Newsroom

Catch up on news from Cerapedics and our developments. Follow us on LinkedIn and X to keep up with all of the latest news.

June 23, 2025 Cerapedics Announces FDA Approval of PearlMatrix™ P-15 Peptide Enhanced Bone Graft, The First and Only Proven Bone Growth Accelerator for Lumbar Fusion Arrow icon
September 24, 2024 Cerapedics’ i-FACTOR P-15 Peptide Enhanced Bone Graft, a Trusted Choice in Bone Graft Solutions, Now Approved for Expanded Indications for Use Arrow icon
January 5, 2024 Cerapedics to Present at the 42nd Annual J.P. Morgan Healthcare Conference Arrow icon
January 4, 2024 Cerapedics Files Final Module of the PMA Application for FDA Approval of a new P-15 Peptide Enhanced Bone Graft for Lumbar Spine Fusion Arrow icon
October 17, 2023 Cerapedics Reinforces Commitment to Level 1 Evidence with Long-Term Results from Six-Year Pivotal IDE Cervical Study Demonstrating 98.6% Spine Fusion Rates in Patients Treated With i-FACTOR® Arrow icon
July 19, 2023 Cerapedics™ Announces Expansion of Headquarters to Support Growth of its Bone Graft Products Arrow icon
October 10, 2022 Cerapedics Appoints Valeska Schroeder Chairman and Chief Executive Officer Arrow icon
February 23, 2022 Cerapedics Completes Enrollment of Pivotal U.S. FDA IDE Study for its P-15L Bone Graft Arrow icon
August 17, 2021 Cerapedics Announces Publication of Results of Study Evaluating the Cost-Effectiveness of i-FACTOR vs. Local Autologous Bone in ACDF Surgery Arrow icon
April 29, 2021 Cerapedics Announces FDA Breakthrough Device Designation Granted for P-15L Bone Graft for the Treatment of Degenerative Disc Disease Arrow icon